KR20170045089A - A pharmaceutical composition for preventing or treating vasculoproliferative disorder comprising herbal mixture extract - Google Patents
A pharmaceutical composition for preventing or treating vasculoproliferative disorder comprising herbal mixture extract Download PDFInfo
- Publication number
- KR20170045089A KR20170045089A KR1020160016503A KR20160016503A KR20170045089A KR 20170045089 A KR20170045089 A KR 20170045089A KR 1020160016503 A KR1020160016503 A KR 1020160016503A KR 20160016503 A KR20160016503 A KR 20160016503A KR 20170045089 A KR20170045089 A KR 20170045089A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- present
- angelica
- hwanggi
- vascular endothelial
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 68
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 title claims description 40
- 235000006533 astragalus Nutrition 0.000 claims abstract description 37
- 230000033115 angiogenesis Effects 0.000 claims abstract description 17
- 230000002792 vascular Effects 0.000 claims abstract description 17
- 230000002062 proliferating effect Effects 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 201000010099 disease Diseases 0.000 claims description 33
- 241001105098 Angelica keiskei Species 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 206010010996 Corneal degeneration Diseases 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 241000125175 Angelica Species 0.000 claims 4
- 208000004611 Abdominal Obesity Diseases 0.000 claims 1
- 241000255789 Bombyx mori Species 0.000 claims 1
- 206010065941 Central obesity Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract description 43
- 230000000694 effects Effects 0.000 abstract description 42
- 240000001810 Angelica gigas Species 0.000 abstract description 30
- 235000018865 Angelica gigas Nutrition 0.000 abstract description 30
- 210000004027 cell Anatomy 0.000 abstract description 17
- 240000006023 Trichosanthes kirilowii Species 0.000 abstract description 4
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 abstract description 4
- 241000045403 Astragalus propinquus Species 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 239000012676 herbal extract Substances 0.000 description 23
- 210000004204 blood vessel Anatomy 0.000 description 20
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 19
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 19
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 19
- 241000411851 herbal medicine Species 0.000 description 19
- 206010029113 Neovascularisation Diseases 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 13
- 239000003814 drug Substances 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 8
- 235000007516 Chrysanthemum Nutrition 0.000 description 8
- 229960003699 evans blue Drugs 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 235000013373 food additive Nutrition 0.000 description 6
- 239000002778 food additive Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 241000723353 Chrysanthemum Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- -1 weights Substances 0.000 description 5
- 244000061520 Angelica archangelica Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 240000002045 Guettarda speciosa Species 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 4
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- 101150071146 COX2 gene Proteins 0.000 description 2
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010058546 Cyclin D1 Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 101150000187 PTGS2 gene Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 108091005960 Citrine Proteins 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012667 Diabetic glaucoma Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 240000008395 Elaeocarpus angustifolius Species 0.000 description 1
- 235000006843 Elaeocarpus angustifolius Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 1
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000020307 Spinal disease Diseases 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000011035 citrine Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Description
The present invention relates to a pharmaceutical composition for the prevention or treatment of angioproliferative diseases comprising a mixed extract of Hwanggi, Angelica gigas and Angelica keiskei as an active ingredient, and a food composition for preventing or improving angioproliferative diseases.
Because every cell in our body feeds oxygen and nutrients from the blood vessels and removes waste products, microvessels spread like nets around every corner of our body. The innermost part of the blood vessel is composed of endothelial cells, and blood vessels are formed based on the three-dimensional arrangement of these endothelial cells.
Vascular diseases are caused by abnormal behavior of the endothelial cells, which is caused by over-production of blood vessels or excessive inhibition of angiogenesis. The diseases such as cancer, diabetic retinopathy, psoriasis, rheumatoid arthritis, chronic inflammation and the like are known as the vascular proliferative diseases in which blood vessels are excessively generated. On the other hand, the angiogenesis inhibitory diseases include myocardial infarction, And delayed regeneration of damaged tissue.
As described above, since the production of blood vessels has been reported to cause various diseases, the mechanism of inhibiting angiogenesis has become a target of various therapeutic agents. Currently used inhibitors of angiogenesis are either induction of apoptosis by inhibiting the activity of certain angiogenic promoters or by inhibiting the growth of vascular endothelial cells or by inducing angiogenic factors or indirect factors controlling endothelial cell viability And the like are used. However, these angiogenesis therapeutic agents have many side effects such as wound healing, or affecting the heart or kidney function, and it is urgent to develop therapeutic agents for vascular diseases without side effects.
Meanwhile, Astragalus membranaceus ) is a perennial herbaceous perennial plant, which is distributed in Korea, Japan, Manchuria, Northeastern China, and Eastern Siberia. It is often said that it is better to plant it as a herb, and to take it out in the autumn in one shot, to remove the outermost root and rootstock, and to dry it in the sun, and to use it without peeling it. It is prescribed for the weakness of the body, fatigue bloating, cold sweat and so on because it has the efficacy such as the tonic, the jihan, the diuretic, the exorcism. In addition, it has been reported that Huangzi extract inhibits angiogenesis by activating Tie2 of vascular endothelial cells, and has an effect of matured, normalized and stabilized blood vessels (Korean Patent Laid-Open No. 10-2014-0009278).
Angelica gigas is a dried perennial roots of Angelica gigas , a perennial paste that is very sweet and very warm. The efficacy of Angelica gigas has a blood-producing effect when blood is lacking. Angelica promotes blood flow in the coronary arteries and stimulates erythropoiesis. In addition, it has been reported that 50% ethanol extract of Angelica gigas Nakai can be used for the treatment of vascular restenosis, vascular stenosis and arteriosclerosis which are directly caused by abnormal proliferation of vascular smooth muscle cells by inhibiting proliferation of aortic smooth muscle cells (Korean Patent Laid-Open No. 10-2010-0047544).
Trichosanthes kirilowii Maximowicz) refers to the perennial root or the root of the yellow horntary which belongs to the genus Cucurbitaceae. There is no smell, the taste is spicy and the quality is cold. Treating petechiae, boils, and nausea when heat causes damage to the juice. It mainly produces lungs and stomach fever, so it helps to quench thirst and softens the body.
As described above, the various pharmacological effects of Hwanggi, Angelica gigas and Chrysanthemum are known, but the effect of these mixed extracts on vascular diseases has not been elucidated.
Under these circumstances, the present inventors have made intensive efforts to develop a therapeutic agent for angioproliferative diseases. As a result, the inventors of the present invention have found that herbal medicine extracts of Hwanggi, Angelica gigas Nakai and Chunghwa are not toxic to normal vascular endothelial cells but inhibit only angiogenesis by vascular endothelial cells The present inventors have completed the present invention.
An object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of angioproliferative diseases, which comprises a mixed extract of Hwanggi, Angelica gigas and Angelica keiskei koidz. As an active ingredient.
Another object of the present invention is to provide a method of preventing or treating angioproliferative diseases comprising administering the composition to a subject.
It is another object of the present invention to provide a food composition for preventing or ameliorating a vascular proliferative disease, which comprises a mixed extract of Hwanggi, Angelica gigas and Angelica keiskei koidz. As an active ingredient.
In one aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating a vascular proliferative disease, which comprises a mixed extract of Hwanggi, Angelica gigas and Angelica keiskei koidz. As an active ingredient.
Terms of the present invention, "Hwang" refers to the scientific name 'Astragalus Plants referred to as ' membranaceus ';" Angelica gigas " is a plant called the " Angelica gigas ";&Quot; and "Chrysanthemum" mean plants referred to as scientific name " Trichosanthes kirilowii Maximowicz ".
In the present invention, the mixed extract of Hwanggi, Angelica gigas and Angelica keiskei can be mixed and used in the same meaning as "SH003 ", and the anti-angiogenic activity of the mixed extract is not known at all until now. .
In the present invention, the hwanggi, angelica, and chrysanthemum are commercially available, purchased or used in nature, or cultivated or cultivated, but the present invention is not limited thereto.
In the present invention, the mixture of Hwanggi, Angelica gigas, and Chunghwa can be extracted with at least one solvent selected from the group consisting of water, an alcohol having 1 to 4 carbon atoms, and a mixed solvent thereof. Specifically, the solvent may be ethanol, more specifically 20 to 40% (v / v) ethanol, but is not limited thereto.
In the present invention, the mixture of Hwanggi, Angelica gigasiferae, and Chunghwa is preferably used in a weight ratio of 1 to 7: 1 to 7: 1 to 7, specifically 1 to 6: 1 to 6: 1 to 6, In a weight ratio of 1 to 5: 1 to 5: 1 to 5, but is not limited thereto.
The term "extract " of the present invention is intended to mean an extract obtained by extracting a mixture of hwanggi, gangwoo and citrine, a diluted solution or concentrate of the extract, a dried product obtained by drying the extract, And extracts of all the formulations that can be formed using the extract.
In the mixed extract of Hwanggi, Angelica gigas and Angelica keiskei according to the present invention, the method for extracting the mixture is not particularly limited and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include hydrothermal extraction, ultrasonic extraction, filtration, and reflux extraction. These may be performed alone or in combination with two or more methods.
The kind of the extraction solvent used for extracting the mixture in the present invention is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the extraction solvent include water, alcohol, and a mixed solvent thereof. These solvents may be used alone or in combination. When an alcohol is used as a solvent, an alcohol having 1 to 4 carbon atoms can be specifically used.
The extract of the present invention may be prepared in the form of a dry powder after extraction.
The term "angioproliferative disorder" as used herein means a disease caused by the proliferation of blood vessels, and may be used in the same sense as angiogenic disease in that it inhibits angiogenesis.
The term "angiogenesis" of the present invention means a physiological process in which new blood vessels are generated from existing blood vessels and can be used in the same meaning as "blood vessel formation" .
The vascular proliferative diseases are collectively referred to as diseases in which the production of new blood vessels is accelerated. For example, the vascular proliferative diseases include diabetic nephropathy caused by excessive production of new adipocytes, Obesity disease; Ocular diseases such as keratitis, corneal degeneration, macular degeneration, diabetic retinopathy, and glaucoma, which are caused by the formation of excessive blood vessels in the eye tissue of the cornea and the like; Spinal diseases such as rheumatoid arthritis and spondyloarthropathy which are caused by abnormally formed blood vessels in cartilage tissue; And malignant tumor diseases in which blood vessels are formed around cancerous growth by excessively secreting angiogenic factors and oxygen and nutrients necessary for growth of cancer cells are supplied and the cancer cells are transferred to other organs through the blood vessels . For example, in the present invention, it has been confirmed that the effect on neovascularization in the ear or the back skin of a mouse is inhibited to inhibit neovascularization in the ear skin of a mouse. As a result, It was found that the anti-angiogenesis-induced diseases were also prevented or treated.
The term "prevention" of the present invention means any action that inhibits or delays angiopoietic diseases by administration of a composition comprising the extract.
The term "treatment" of the present invention means all the actions that improve or ameliorate the symptom of angiopoietic disease upon administration of the composition containing the extract.
In one specific example of the present invention, in order to confirm the inhibitory effect on the angiogenesis-inhibiting effect of the mixed extract of Hwanggi, Angelica gigas and Angelica keiskei, the extract was treated with vascular endothelial cells, And inhibited neovascularization in the ear or back skin of mice (Figs. 2 to 5 and Figs. 8 to 9).
In another embodiment, an extract comprising a mixture of herb extracts, Angelica keiskei, and Angelica keiskei, which make up the mixed herbal extract, at a weight ratio of 5: 1: 1, 1: 5: 1 or 1: 1: 5, (1: 1: 1) showed the same effect as the extracts contained (FIG. 10). This suggests that the mixed herbal medicine extract prepared by changing the weight ratio of each component can inhibit not only the migration of HUVEC but also tube formation of HUVEC, infiltration of HUVEC and angiogenesis of an in vivo animal model.
Therefore, the mixed extract of Hwanggi, Angelica gigas, and Angelica gigas Nakai of the present invention has an effect of inhibiting the formation of new blood vessels, so that it can be effectively used for the prevention or treatment of angiopoietic diseases caused by the new blood vessels Could know.
In another aspect for solving the above object, the present invention provides a pharmaceutical composition for treating a vascular proliferative disease, comprising the step of administering the pharmaceutical composition to a subject other than a human, And a method for preventing or treating the disease.
The term "administering" of the present invention means introducing a composition comprising said extract into a subject in an appropriate manner.
The term "individual" of the present invention means all animals such as rats, mice, livestock, etc., including humans who have developed or are capable of developing angioproliferative diseases. As a specific example, it may be a mammal including a human.
The composition of the present invention is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" of the present invention means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level is determined by the kind and severity of the subject, The activity of the compound, the sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts. For example, the mixed extract of Hwanggi, Angelica gigas and Angelica keiskei can be administered as an active ingredient at a dose of 0.01 to 500 mg / kg per day, specifically 10 to 100 mg / kg, Or may be administered in divided doses. In addition, the pharmaceutical composition of the present invention may contain 0.001 to 50% by weight of the extract, based on the total weight of the composition.
The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. And can be administered singly or multiply. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without adverse effect, and can be easily determined by those skilled in the art.
The pharmaceutical composition for preventing or treating a vascular proliferative disease of the present invention may contain a pharmaceutically acceptable carrier, excipient or diluent in addition to the above-described effective ingredient. Examples of the carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
The pharmaceutical compositions of the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols or the like, oral preparations, suppositories or sterilized injection solutions according to a conventional method have. Specifically, when formulating, it can be prepared by using diluents or excipients such as fillers, weights, binders, humectants, disintegrants, surfactants and the like commonly used. Solid formulations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, and the like. Such a solid preparation may be prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration, liquid paraffin, and various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like. Examples of the suppository base include withexol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
The pharmaceutical composition of the present invention may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) depending on the intended method, and the dose may be determined depending on the condition and the weight of the patient, The mode of administration, the route of administration, and the time, but may be appropriately selected by those skilled in the art.
In another aspect of the present invention, the present invention provides a food composition for preventing or ameliorating a vascular proliferative disease, which comprises a mixed extract of Hwanggi, Angelica gigas and Angelica keiskei koidz. As an active ingredient. Herein, the definitions of the extracts and angioproliferative diseases are as described above.
The term " improvement "of the present invention means any action that at least reduces the degree of symptom associated with the condition being treated by administration of the composition comprising the extract.
When the food composition of the present invention is used as a food additive, the composition can be added as it is, or can be used together with other food or food ingredients, and can be suitably used according to a conventional method.
Specifically, the food composition may be any one of meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, gum, ice cream, soup, beverage, tea, functional water, Lt; / RTI >
It is also possible to use a variety of nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and heavies (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, The composition may contain a colloidal thickener, a pH adjusting agent, a stabilizer, a preservative, a glycerin, an alcohol, a carbonating agent used in a carbonated beverage, and the like, as well as flesh for the production of natural fruit juice and fruit juice drinks and vegetable drinks . These may be used alone or in combination of two or more.
The above food composition may further contain food additives, and whether or not the food additive is suitable as a "food additive" includes, unless otherwise specified, the standard for the relevant item in accordance with the general provisions of the Food Additives Ordinance approved by the Food and Drug Administration, And criteria.
Examples of the products listed in the above-mentioned "food additives" include natural products such as ketones, chemical products such as glycine, potassium citrate, nicotinic acid and cinnamic acid, coloring matter, licorice extract, crystalline cellulosic, high- , A sodium L-glutamate preparation, a noodle-added alkaline agent, a preservative preparation, a tar coloring agent, and the like.
At this time, the extract according to the present invention, which is added to foods containing beverages in the process of preparing the food composition, can be appropriately increased or decreased as needed. Specifically, the extract can be added in an amount of 0.01 to 10 wt% But is not limited thereto.
Although herbal medicine extracts containing the hwanggi, angelica, and chrysanthemum of the present invention do not show toxicity to vascular endothelial cells, they have an effect of inhibiting angiogenesis by vascular endothelial cells. Therefore, May be useful for the treatment of proliferative diseases.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a table showing a list of herbal drugs constituting herbal medicine extract (SH003) of the present invention. The herbal medicine extract of the present invention contains Hwanggi, Angelica gigas and Chrysanthemum.
FIG. 2 is a graph showing the effect of SH003 of the present invention on the growth of vascular endothelial cell HUVECs by vascular endothelial growth factor (VEGF).
FIG. 3 shows the effect of SH003 of the present invention on VEGF-mediated migration of vascular endothelial HUVEC, wherein A is an image showing the cell migration of HUVEC and B is a graph showing the number of migrated HUVEC.
FIG. 4 shows the effect of SH003 of the present invention on VEGF-induced vascular endothelial cell HUVEC, wherein A is an image showing a tube formed by HUVEC and B is a graph showing the number of tubes formed by HUVEC .
5 shows the effect of SH003 of the present invention on invasion of vascular endothelial cell HUVEC by VEGF, wherein A is an image showing HUVEC infiltrated with matrigel, B is an image showing infiltration of Matrigel HUVEC < / RTI >
FIG. 6 is an image showing the effect of SH003 of the present invention on angiogenesis-related signaling mechanism in vascular endothelial cell HUVEC, wherein A is an image showing the degree of phosphorylation of NF-κB signal transduction related protein, It is an image showing the degree of phosphorylation of protein.
FIG. 7 is an image showing the effect of SH003 of the present invention on the expression of tumor angiogenesis-related genes in vascular endothelial cell HUVEC, wherein A shows the results of treating
8 shows the effect of SH003 of the present invention on neovascularization in the ear of a mouse, wherein A is an image obtained by staining a new blood vessel using Evans Blue, and B is an image obtained by measuring the amount of the stained Evans blue FIG.
9 shows the effect of SH003 of the present invention on the development of neovascularization in the dorsal skin of a mouse, wherein A is an image obtained by staining a new blood vessel with evans blue, and B is an amount of the stained Evans blue And the results are shown in FIG.
FIG. 10 is an image and a graph showing the effect of VEGF-induced vascular endothelial cell HUVEC mobility on the extract prepared by varying the mixture ratio of Hwanggi, Angelica gigas, or flower starch constituting SH003 of the present invention, wherein A represents cell migration of HUVEC And B is a graph showing the number of moved HUVECs.
Hereinafter, the present invention will be described in more detail by way of examples. However, the following examples are illustrative of the present invention, and the contents of the present invention are not limited to the following examples.
Manufacturing example 1. Preparation of mixed herbal extracts
As shown in Fig. 1, mixed herbal medicine extracts were prepared using 1 g of Hwanggi, 1 g of oriental ginseng, and 1 g of astragalus powder.
A mixed extract of Hwanggi, Angelica gigas and Angelica keiskei koidz. As active ingredients in the composition of the present invention can be obtained by the following method.
First, Hwanggi, Angelica gigas and Chrysanthemum were washed with water to remove foreign matter. Then, the hwanggi, angelica, and cyanobacteria were mixed and then completely dipped in a 20-fold volume of 30% (v / v) ethanol. The extract was filtered and concentrated under reduced pressure to obtain a mixed extract of the final hwanggi, angelica and chrysanthemum.
Example 1. Vascular endothelial cells Mixed herbal medicines for growth Analysis of the effect of extracts
In order to examine the effect of the mixed herbal medicine extract (SH003) of the present invention on the vascular endothelial cell growth, HUVEC, a vascular endothelial cell line, was treated with Vascular endothelial growth factor (VEGF) and mixed herbal medicine extract.
Specifically, HUVEC, a vascular endothelial cell line cultured on 96-well plates, was treated with 50 ng / ml of VEGF and 5 to 50 μg / ml of herbal extracts, and then cultured for 24 hours at 37 ° C., And cultured at 5% CO 2 . Then, each cell was treated with MTT (3- (4,5-Dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) reagent and further cultured for 2 hours. Then, the supernatant was removed, DMSO (dimethyl sulfoxide) was added. The absorbance was finally measured at a wavelength of 590 nm, and the absorbance value was compared with the control group in which no substance was treated.
As a result, as shown in FIG. 2, even if the concentration of SH003 was increased, the viability of the cells was not decreased. Thus, it was confirmed that the mixed herbal extract of the present invention had no effect on vascular endothelial cell growth regardless of the concentration .
Example 2. Effect of mixed herbal extracts on migration of vascular endothelial cells
In order to examine the effect of the herbal extract of the present invention on the vascular endothelial cell mobility, a scratching assay was performed.
Specifically, HUVEC, a vascular endothelial cell line, was cultured on a 12-well plate, and cells were scraped off to make gaps between the cells. The cells were treated with 50 ng / ml of VEGF and 10 to 50 μg / ml of herbal extracts for 9.5 hours, and the number of transferred cells was measured.
As a result, as shown in FIG. 3, as the concentration of SH003 increased, the number of migrated cells decreased, and it was confirmed that the mixed herbal extract of the present invention significantly inhibited cell migration of HUVEC, a vascular endothelial cell line.
Example 3. Vessels of vascular endothelial cells Mixed herbal medicines for production Analysis of the effect of extracts
In order to examine the effect of the herbal extract of the present invention on angiogenesis of vascular endothelial cells, a tube formation assay was performed.
Specifically, HUVEC, a vascular endothelial cell line, was cultured in an upper chamber coated with matrigel, treated with a mixture of 50 ng / ml of VEGF and 10 to 50 μg / ml of herbal medicine extract for 6 hours , And then the number of tubes formed was measured.
As a result, as shown in FIG. 4, as the concentration of SH003 increased, the number of the tubes formed by the vascular endothelial cells decreased, and the mixed herbal medicine extract of the present invention significantly inhibited the tube forming ability of the vascular endothelial cell line HUVEC Respectively.
Example 4. Analysis of the effects of mixed herbal extracts on the invasion of vascular endothelial cells
In order to examine the effect of the mixed herbal extract of the present invention on the infiltration of vascular endothelial cells, invasion assay was performed.
Specifically, HUVEC, a vascular endothelial cell line, was cultured in an upper chamber coated with matrigel, treated with 50 ng / ml of VEGF and 10 to 50 μg / ml of herbal extracts for 7 days Lt; / RTI > Then, the infiltrated cells were stained with a crystal violet, and the number thereof was measured.
As a result, as shown in FIG. 5, as the concentration of SH003 was increased, the number of infiltrating cells was decreased. Thus, it was confirmed that the herbal extract of the present invention significantly inhibited the cell infiltration of HUVEC, a vascular endothelial cell line Respectively.
Example 5. Vascular endothelial neovascularization signaling Mixed herbal medicine for the mechanism Analysis of the effect of extracts
Example 5-1. NF - κB Signal transmission Mixed herbal medicine for the mechanism Analysis of the effect of extracts
Protein expression assays were performed to examine the effects of the herbal extracts of the present invention on the NF-κB signaling pathway involved in vascular endothelial cell neovascularization.
Specifically, HUVEC, a vascular endothelial cell line, was treated with 50 ng / ml of VEGF and 20 μg / ml of SH003 and cultured for 24 hours. The cultured cells were washed to obtain proteins, electrophoresed, and then electrophoresed and then expressed in cells using p-IKKα / β, IKKα, p-IκBα, IκBα, p-NF-κB, NF-κB or α- The amount of protein was compared.
As a result, as shown in Fig. 6A, it was confirmed that the herbal extract of the present invention inhibited the phosphorylation of NF-κB involved in the vascular endothelial cell neovascularization mechanism.
Example 5-2. STAT3 Signal transmission Mixed herbal medicine for the mechanism Analysis of the effect of extracts
To examine the effects of the herbal extracts of the present invention on the STAT3 signal transduction pathway involved in vascular endothelial cell neovascularization, a protein expression assay was performed.
Specifically, the electrophoresis was performed in the same manner as in Example 5-1, and then the amounts of proteins expressed in the cells were compared using p-STAT3, STAT3 or α-tubulin antibody.
As a result, as shown in Fig. 6B, it was confirmed that the herbal extract of the present invention inhibited the phosphorylation of STAT3 related to the vascular endothelial cell neovascularization mechanism.
Example 6. Vascular endothelial neovascularization-related genes Mix for expression Analysis of the effects of herbal extracts
To examine the effect of the herbal extract of the present invention on the expression of genes (MMP-9, Bcl-2, Cyclin D1 and Cox-2) involved in vascular endothelial cell neovascularization, a protein expression assay was performed .
Specifically, HUVEC, a vascular endothelial cell line, was treated with 50 ng / ml of VEGF and 20 μg / ml of mixed herbal extract and cultured for 4 to 24 hours. The cultured cells were washed to obtain proteins, and the amounts of proteins expressed in the cells were compared using MMP-9, Bcl-2, Cyclin D1, Cox-2 or α-tubulin antibody.
As a result, as shown in FIG. 7, it was confirmed that the mixed herbal extract of the present invention remarkably suppressed the expression of VEGF-related MMP-9 in vascular endothelial cells.
Example 7. Invivo (in vivo In animal models Mixed herbal medicines for neovascularization Analysis of the effect of extracts
Evans blue assay was performed to examine the effect of the mixed herbal extract of the present invention on neovascularization in the ear or the back skin of a mouse.
Specifically, mice were treated with 50 ng / ml of VEGF and 20 μg / ml of SH003 in the skin blood vessels of the mice, and after 30 minutes, Evans blue was injected. Mice were sacrificed and the ears or back tissues were isolated and photographed, and then Evans blue solution, which was immersed in formamide for 24 hours, and evolved from the ear or back tissue, was measured.
As a result, as shown in FIG. 8, in the group treated with SH003 of the present invention, the degree of staining with Evans blue was reduced compared with the group treated with VEGF, whereby SH003 inhibited neovascularization in the ear skin of mice Respectively. In addition, as shown in Fig. 9, in the group treated with SH003 of the present invention, the degree of staining with Evans blue was decreased as compared with the group treated with VEGF, Respectively.
From the above results, it was confirmed that the mixed extract of Hwanggi, Angelica gigas and Angelica keiskei according to the present invention has an excellent effect on the inhibition of angiogenesis.
Example 8. Mobility of vascular endothelial cells according to mixing ratio of mixed herbal extracts
The following experiments were carried out to confirm the ratio of Hwanggi, Angelica gigas and Angelica keiskei showing the best inhibitory effect on angiogenesis.
Specifically, mixed herbal medicine extracts containing Hwanggi, Angelica gigas and Angelica keiskei at a weight ratio of 5: 1: 1, 1: 5: 1 or 1: 1: 5, respectively, were further prepared. Then, a scratching assay using each of the extracts was carried out according to the method of Example 2 above.
As a result, as shown in Fig. 10, the extract of the mixture containing Hwanggi, Angelica and Angelica fractions at a weight ratio of 5: 1: 1, 1: 5: 1 or 1: 1: 5, respectively, had a weight ratio of 1: It was confirmed that the cell migration of HUVEC, which is a vascular endothelial cell, can be remarkably suppressed to a degree similar to or better than that of the extract containing HUVEC.
The mixed herbal medicine extract according to the present invention contains Hwanggi, Angelica gigas and Chrysanthemum at a weight ratio of 1: 1: 1 in a weight ratio of 5: 1: 1, 1: 5: 1 or 1: Which is the same as that of the extract. This suggests that the mixed herbal medicine extract prepared by changing the weight ratio of each component can inhibit not only the migration of HUVEC but also tube formation of HUVEC, infiltration of HUVEC and angiogenesis of an in vivo animal model.
From the above description, it will be understood by those skilled in the art that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. In this regard, it should be understood that the above-described embodiments are to be considered in all respects as illustrative and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention without departing from the scope of the present invention as defined by the appended claims.
Claims (6)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150144142 | 2015-10-15 | ||
| KR1020150144142 | 2015-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170045089A true KR20170045089A (en) | 2017-04-26 |
Family
ID=58705000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160016503A KR20170045089A (en) | 2015-10-15 | 2016-02-12 | A pharmaceutical composition for preventing or treating vasculoproliferative disorder comprising herbal mixture extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20170045089A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115777826A (en) * | 2022-11-14 | 2023-03-14 | 上海市杨浦区青少年科技站 | An antifatigue chewing gum containing radix Angelicae sinensis and radix astragali extract |
-
2016
- 2016-02-12 KR KR1020160016503A patent/KR20170045089A/en not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115777826A (en) * | 2022-11-14 | 2023-03-14 | 上海市杨浦区青少年科技站 | An antifatigue chewing gum containing radix Angelicae sinensis and radix astragali extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9649351B2 (en) | Anti-angiogenic agents and anti-obesity substances applied with anti-angiogenesis from natural products | |
| KR101651907B1 (en) | Composition for Prevention or Treatment of Obesity Comprising Tenebrio molitor larva extract or Tenebrio molitor larva suspension | |
| KR101784383B1 (en) | Anticancer composition comprising herbal mixture extract | |
| KR102028634B1 (en) | A composition for preventing or treating menopausal cardiovascular disease comprising Cuscuta japonica Chois extract | |
| KR101735239B1 (en) | A pharmaceutical composition for preventing or treating cancer comprising Danggui-Sayuk-Ga-Osuyu-Saenggang-Tang | |
| KR20170109703A (en) | A pharmaceutical composition for preventing or treating cancer comprising fractions of herbal mixture extract | |
| KR20170045089A (en) | A pharmaceutical composition for preventing or treating vasculoproliferative disorder comprising herbal mixture extract | |
| KR20200074360A (en) | Paeonia lactiflora extract-containing composition for treatment of osteoporosis via mechanism of inhibiting differentiation to osteoclast or promoting differentiation to osteoblast | |
| KR102122408B1 (en) | Composition for preventing, ameliorating or treating andropause syndrome comprising roasted Glycyrrhiza uralensis extract as effective component | |
| KR101896815B1 (en) | Health functional food composition for anorexia improvement and pharmaceutical composition for preventing or treating anorexia improvement | |
| KR20150060653A (en) | Pharmaceutical compositions for the treatment of cancer metastasis or inhibition of metastasis containing Quassia undulata extracts as active fractions | |
| KR102487651B1 (en) | A composition for preventing, improving or treating sarcopenia comprising extracts of wheat sprout | |
| KR102536959B1 (en) | Composition for preventing, improving, or treating cachexia containing extract of Raphani Semen | |
| KR102275268B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
| KR102142924B1 (en) | Pharmaceutical composition for preventing or treating osteoporosis by araliae continentalis radix extract | |
| KR102160627B1 (en) | Pharmaceutical composition for preventing or treating bone disease comprising extracts of branches of Hovenia dulcis Thunb | |
| KR20190103665A (en) | Food composition for improving or preventing obesity containing extract of saururus chinensis | |
| KR102410703B1 (en) | Composition for preventing, improving or treating bone disease comprising Pyrrosia lingua extract as effective component | |
| KR102475985B1 (en) | Composition for preventing or treating rheumatoid arthritis comprising combination extract containing Rhei Rhizoma, Scutellariae Radix and Coptidis Rhizoma | |
| KR102138860B1 (en) | Composition for lowering intraocular pressure regulating comprising extract of maple leaves | |
| KR101636348B1 (en) | Pharmaceutical composition and functional food composition for prevention or treatment of angiogenesis-related diseases comprising Meliosma oldhamii Maxim extraction | |
| KR102633837B1 (en) | Method for preparing mixture of Scutellariae Radix extract and Coptidis Rhizoma extract having excellent improvement and treatment for rheumatoid arthritis, and composition for preventing or treating rheumatoid arthritis comprising thereof | |
| KR102197296B1 (en) | Pharmaceutical composition for preventing or treating lung cancer comprising extract of Schoenoplectus triqueter | |
| KR20110078237A (en) | Composition for treating or preventing obesity containing eriobotrya japonica extract | |
| KR100777351B1 (en) | Health food comprising extracts of germinated Rhynchosia Volubilis as active ingredients for prevention or treatment of osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |